REGISTER RECORD · clinicaltrials.gov
NCT02020070
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | COMPLETED: completed |
|---|---|
| Register last updated | 2026-07-06 |
| Retrieved by this site | 2026-10-03 |
| Source | https://clinicaltrials.gov/study/NCT02020070 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.